Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Evaluation of Her-2/neu gene status in osteosarcoma by fluorescence in situ hybridization and multiplex and monoplex polymerase chain reactions.

Willmore-Payne C, Holden JA, Zhou H, Gupta D, Hirschowitz S, Wittwer CT, Layfield LJ.

Arch Pathol Lab Med. 2006 May;130(5):691-8.

PMID:
16683887
2.

Aberrant expression of the human epidermal growth factor receptor 2 oncogene is not a common feature in osteosarcoma.

Baumhoer D, Smida J, Specht K, Bink K, Quintanilla-Martinez L, Rosemann M, Siggelkow H, Nathrath WB, Atkinson MJ, Bielack S, Jundt G, Nathrath M.

Hum Pathol. 2011 Jun;42(6):859-66. doi: 10.1016/j.humpath.2010.09.016.

PMID:
21292304
3.
4.

Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas.

Maitra A, Wanzer D, Weinberg AG, Ashfaq R.

Cancer. 2001 Aug 1;92(3):677-83.

PMID:
11505415
5.

Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification.

Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE.

J Pediatr Hematol Oncol. 2003 Jan;25(1):27-32.

PMID:
12544770
6.

Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma.

Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L.

Clin Cancer Res. 2002 Mar;8(3):788-93.

8.

HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study.

Somers GR, Ho M, Zielenska M, Squire JA, Thorner PS.

Pediatr Dev Pathol. 2005 Sep-Oct;8(5):525-32.

PMID:
16211448
9.

Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas.

Anninga JK, van de Vijver MJ, Cleton-Jansen AM, Kristel PM, Taminiau AH, Nooij M, Egeler RM, Hogendoorn PC.

Eur J Cancer. 2004 May;40(7):963-70.

PMID:
15093570
10.

HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.

Ross JS, Sheehan C, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman R, Fisher HA, Muraca PJ.

Hum Pathol. 1997 Jul;28(7):827-33.

PMID:
9224752
11.

HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis.

Tsai JY, Aviv H, Benevenia J, Chang VT, Patterson F, Aisner S, Hameed M.

Cancer Invest. 2004;22(1):16-24.

PMID:
15069760
12.

Isolation of osteosarcoma-associated amplified DNA sequences using representational difference analysis.

Simons A, Janssen IM, Suijkerbuijk RF, Veth RP, Pruszczynski M, Hulsbergen-van de Kaa CA, du Manoir S, Geurts van Kessel A.

Genes Chromosomes Cancer. 1997 Oct;20(2):196-200.

PMID:
9331570
13.

Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors.

Flint AF, U'Ren L, Legare ME, Withrow SJ, Dernell W, Hanneman WH.

Vet Pathol. 2004 May;41(3):291-6.

PMID:
15133183
14.

Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis.

Wen YH, Koeppen H, Garcia R, Chiriboga L, Tarlow BD, Peters BA, Eigenbrot C, Yee H, Steiner G, Greco MA.

Hum Pathol. 2007 Aug;38(8):1184-91.

PMID:
17509661
15.
16.

Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma.

Ross JS, Sheehan CE, Hayner-Buchan AM, Ambros RA, Kallakury BV, Kaufman RP Jr, Fisher HA, Rifkin MD, Muraca PJ.

Cancer. 1997 Jun 1;79(11):2162-70.

PMID:
9179063
17.

HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization.

Odicino FE, Bignotti E, Rossi E, Pasinetti B, Tassi RA, Donzelli C, Falchetti M, Fontana P, Grigolato PG, Pecorelli S.

Int J Gynecol Cancer. 2008 Jan-Feb;18(1):14-21.

PMID:
17451461
20.
Items per page

Supplemental Content

Support Center